Surface Oncology

$7.86
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+1.42%) Today
$0.00 (0.00%) As of 4:05 AM EST after-hours

Why Robinhood?

You can buy or sell SURF and other stocks, options, and ETFs commission-free!

About SURF

Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388); a clinical-stage collaboration with Novartis targeting CD73 (NZV930); and two preclinical programs, each focused primarily on activating natural killer or depleting regulatory T cells. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. The listed name for SURF is Surface Oncology, Inc. Common Stock.

CEO
J. Jeffrey Goater
Employees
49
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
319.72M
Price-Earnings Ratio
Dividend Yield
Average Volume
761.78K
High Today
$8.00
Low Today
$7.73
Open Price
$7.85
Volume
425.39K
52 Week High
$10.25
52 Week Low
$1.38

Collections

SURF Earnings

-$0.64
-$0.18
$0.28
$0.74
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, Pre-Market

You May Also Like